Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $30.63

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been given an average rating of “Moderate Buy” by the ten ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $30.63.

A number of research firms have weighed in on FDMT. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. BMO Capital Markets downgraded 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $40.00 to $15.00 in a research report on Monday, January 13th. Chardan Capital lowered their price target on 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Leerink Partners lowered their price target on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. Finally, Royal Bank of Canada lowered their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Millennium Management LLC increased its holdings in 4D Molecular Therapeutics by 1,607.1% during the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company’s stock valued at $7,913,000 after purchasing an additional 1,337,497 shares during the period. Braidwell LP increased its holdings in 4D Molecular Therapeutics by 231.7% during the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock valued at $13,247,000 after purchasing an additional 855,990 shares during the period. JPMorgan Chase & Co. increased its holdings in 4D Molecular Therapeutics by 159.5% during the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company’s stock valued at $4,568,000 after purchasing an additional 504,086 shares during the period. Norges Bank purchased a new position in 4D Molecular Therapeutics during the 4th quarter valued at about $2,790,000. Finally, Cubist Systematic Strategies LLC increased its holdings in 4D Molecular Therapeutics by 2,084.5% during the 4th quarter. Cubist Systematic Strategies LLC now owns 448,831 shares of the company’s stock valued at $2,500,000 after purchasing an additional 428,285 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $3.79 on Monday. The firm has a market capitalization of $175.48 million, a price-to-earnings ratio of -1.33 and a beta of 2.83. 4D Molecular Therapeutics has a 52-week low of $3.66 and a 52-week high of $36.25. The stock has a fifty day moving average of $4.77 and a 200 day moving average of $7.60.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.10). Equities analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.